397 related articles for article (PubMed ID: 27098896)
1. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
[TBL] [Abstract][Full Text] [Related]
2. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.
de Jong MC; Scheffer GL; Broxterman HJ; Hooijberg JH; Slootstra JW; Meloen RH; Kreitman RJ; Husain SR; Joshi BH; Puri RK; Scheper RJ
Clin Cancer Res; 2003 Oct; 9(13):5009-17. PubMed ID: 14581376
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
6. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
7. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
Rigalli JP; Tocchetti GN; Arana MR; Villanueva SS; Catania VA; Theile D; Ruiz ML; Weiss J
Cancer Lett; 2016 Jun; 376(1):165-72. PubMed ID: 27033456
[TBL] [Abstract][Full Text] [Related]
8. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.
Rocha Gda G; Oliveira RR; Kaplan MA; Gattass CR
Eur J Pharmacol; 2014 Oct; 741():140-9. PubMed ID: 25111243
[TBL] [Abstract][Full Text] [Related]
9. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
Xu HB; Li L; Fu J; Mao XP; Xu LZ
Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
11. Natural products as multidrug resistance modulators in cancer.
Kumar A; Jaitak V
Eur J Med Chem; 2019 Aug; 176():268-291. PubMed ID: 31103904
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
13. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
15. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases.
Yang AK; Zhou ZW; Wei MQ; Liu JP; Zhou SF
Curr Top Med Chem; 2010; 10(17):1732-56. PubMed ID: 20645920
[TBL] [Abstract][Full Text] [Related]
16. MRP1 and its role in anticancer drug resistance.
Lu JF; Pokharel D; Bebawy M
Drug Metab Rev; 2015; 47(4):406-19. PubMed ID: 26541366
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the study of micelle delivery system reversing multidrug resistance].
Diao YY; Han M; Chen DW; Gao JQ
Yao Xue Xue Bao; 2009 Jul; 44(7):710-5. PubMed ID: 19806907
[TBL] [Abstract][Full Text] [Related]
19. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
20. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
